Alnylam presents cardiovascular drug data at medical conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
March 30, 2026 1:00 PM EDTVutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger
Findings Reinforce Consistent Benefits of Vutrisiran Across ATTR-CM Disease Spectrum, Including Patients with Most Advanced Disease and Diastolic Dysfunction
Real-World Data Demonstrate High Adherence and Persistence of Quarterly HCP-Administered Dosing with Vutrisiran
Pooled Phase 2 Safety Data Reinforce Encouraging Safety Profile for Zilebesiran Across a Broad Population of Patients with Hypertension
CAMBRIDGE, Mass.--(BUSINESS... More
